FIELD: biotechnology.
SUBSTANCE: invention relates to FGFR inhibitors and their use as antitumor agents. A crystalline form of N-(2-((6-(3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-methylureido)pyrimidin-4-yl)amino)-5-(4-ethylpiperazin-1-yl)phenyl)acrylamide in the form of a free base is proposed. Methods for producing the specified crystalline form and its application for the treatment of hepatocellular carcinoma are also proposed.
EFFECT: proposed crystalline form is stable during storage and well soluble.
22 cl, 19 dwg, 10 tbl, 17 ex
| Title | Year | Author | Number |
|---|---|---|---|
| FGFR4 INHIBITORS | 2014 |
|
RU2715708C2 |
| COMBINATION THERAPY FOR HEPATOCELLULAR CARCINOMA | 2017 |
|
RU2769251C2 |
| COMBINATION THERAPIES FOR TREATMENT OF HEPATOCELLULAR CARCINOMA | 2019 |
|
RU2787993C2 |
| INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR | 2013 |
|
RU2679130C2 |
| FGFR INHIBITOR AND ITS APPLICATION | 2018 |
|
RU2745035C1 |
| QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | 2015 |
|
RU2721723C2 |
| FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | 2014 |
|
RU2704112C2 |
| INDAZOLE COMPOUNDS AS FGFR KINASE INHIBITORS, PREPARATION AND USE THEREOF | 2015 |
|
RU2719428C2 |
| PYRIMIDINE-UREA DERIVATIVES AS KINASE INHIBITORS | 2005 |
|
RU2430093C2 |
| FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS AND USE THEREOF | 2017 |
|
RU2732127C1 |
